Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals
Allergy · 2024
DOI: 10.1111/all.15911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von David González-de-Olano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: Anaphylaxis, Mastocytosis, Mast Cell Activation Syndrome. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Fundación Española de Mastocitosis, Fundación para la investigación Biomédica del Hospital Ramón y Cajal IRYCIS, Fundación Sociedad Española de Alergología e Inmunología Clínica.
Abstract (Originalsprache)
Background
A close association between hereditary alpha‐tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship between HAT and the diagnostic subtypes and clinical features of MC disorders still remains to be established.
Objective
To determine the prevalence of HAT in healthy donors (HD) vs patients with different diagnostic subtypes of MC activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease.
Methods
A total of 959 subjects were studied including 346 healthy donors (HD), 464 mastocytosis, and 149 non‐clonal MCAS patients. Molecular studies to assess the TPSAB1 genotype were performed, and data on serum baseline tryptase (sBT) and basal MC‐mediator release episodes and triggers of anaphylaxis were collected.
Results
HAT was detected in 15/346 (4%) HD versus 43/149 (29%) non‐clonal MCAS and 84/464 (18%) mastocytosis cases. Among mastocytosis, HAT was more frequently found in patients with MC‐restricted KIT D816V (21% vs. 10% among multilineage KIT D816V patients; p = .008). Overall, median sBT was higher in cases presenting with HAT (28.9 vs. 24.5 ng/mL; p = .008), while no significant differences in sBT were observed among HAT + mastocytosis patients depending on the presence of 1 vs. ≥2 extra copies of the α‐tryptase gene (44.1 vs. 35.2 ng/mL, p > .05). In turn, anaphylaxis was more frequently observed in HAT + versus HAT − mastocytosis patients (76% vs. 65%; p = .018), while HAT + and HAT − patients who did not refer anaphylaxis as the presenting symptom ( n = 308) showed a similar prevalence of subsequent anaphylaxis (35% vs. 36%, respectively).
Conclusion
The frequency of HAT in MC disorders varies according to the diagnostic subtype of the disease. HAT does not imply a higher risk (and severity) of anaphylaxis in mastocytosis patients in whom anaphylaxis is not part of the presenting symptoms of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
- Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Salamanca, Spain.
- Department of Medicine and Citometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.
- Sequencing Service (NUCLEUS), Universidad de Salamanca, Salamanca, Spain.
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
- Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain.
ORCID-Profile: David González-de-Olano, Paula Navarro-Navarro, Javier I Muñoz-González, Laura Sánchez-Muñoz, Ana Henriques, Ana de-Andrés-Martín, Andrea Mayado, María Jara-Acevedo, Andrés C García-Montero, Alberto Orfao, Iván Álvarez-Twose
Förderung
- Fundación Española de Mastocitosis
- Fundación para la investigación Biomédica del Hospital Ramón y Cajal IRYCIS
- Fundación Sociedad Española de Alergología e Inmunología Clínica
- Instituto de Salud Carlos III (reference PI22/01657)
Zitieren
APA
González-de-Olano, D., Navarro-Navarro, P., Muñoz-González, J. I., Sánchez-Muñoz, L., Henriques, A., de-Andrés-Martín, A., Peralta-Arjonilla, D., Mayado, A., Jara-Acevedo, M., García-Montero, A. C., Orfao, A., & Álvarez-Twose, I. (2024). Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. https://doi.org/10.1111/all.15911
Vancouver
González-de-Olano D, Navarro-Navarro P, Muñoz-González JI, Sánchez-Muñoz L, Henriques A, de-Andrés-Martín A, et al. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. 2024. doi:10.1111/all.15911
BibTeX
@article{GonzlezdeOlano2024,
author = {González-de-Olano, David and Navarro-Navarro, Paula and Muñoz-González, Javier I and Sánchez-Muñoz, Laura and Henriques, Ana and de-Andrés-Martín, Ana and Peralta-Arjonilla, Dolores and Mayado, Andrea and Jara-Acevedo, María and García-Montero, Andrés C and Orfao, Alberto and Álvarez-Twose, Iván},
title = {Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.15911}
}
EUVIMED